Reading PTCT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PTCT free→
PTC Therapeutics, Inc. (PTCT)
NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Intact
$76.77+2.17%
Close 2026-06-15 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, and management's recent track record has been steady, with capital-friendly moves. However, the company was unprofitable over the past year, so its earnings quality can't be assessed. Peer multiples imply a price about 46% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak or earnings quality is fragile. Key factors to watch include guidance changes and sector trends, particularly the performance of bellwethers like VRTX, REGN, and ARGX. This read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $6.23B
- Employees
- —
- IPO date
- 2006-03-31
- Next earnings
- 2026-08-06
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 2 valuation methods, at three horizons. Current price $76.77. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryinexpensive
$126.26consensus
Range $88.90 – $163.62
vs price: -42% below
Method agreement — · 2 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearfull
$67.84consensus
Range $47.47 – $88.21
vs price: +8% above
Method agreement — · 2 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Durable premiumlow confidence
At $77 the market pays 3× p/s — above the 3× p/s peer median but in line with its own 3× history. That premium reflects a durable franchise our peer-anchored $134 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $82–$120. Not investment advice.
Multiple (P/S)
3.5x
peer 2.5x · own history 3.4x
Premium
1.4x peer
1.0x its own history
Growth the price needs
-43%
our forecast -60%
Our fair value
$133.78
range $95.02 – $172.55
Analyst range(a guide on our number, not a target)Our number is above the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
inexpensivecheap — value-trap risk12-month view
What's priced inStretched
The price implies about 43% below a flat-multiple fair value, ahead of our forecast of about -60%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Low fragilityrisk posture, not a price call
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
74th pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted 1.17x of net income into operating cash flow.
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
stableEarnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bullishEPS revised +172.5% / 30d, n=3for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $-0.46 → $0.33 (+172.5% / 30d). 0 raised, 0 cut, 3 covering analysts.
Rating actions
1 upgrade, 0 downgrades / 30d, 0 maintained. 73% of analysts rate Buy.
Price target activity
1 PT revisions / 30d. Avg target 21.5% above current price.
Material events
1 positive, 0 negative / 30d. See F4 management tile for the event list.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
Sector context
Intermediate · WeeklyManagement scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: strong
- Capital allocation
- strong
- Earnings discipline
- neutral
- Margin discipline
- neutral
- Balance sheet
- neutral
- Post-call reaction
- strong
A guidance track record builds as the company issues and delivers on guidance.
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$150.
How much price usually moves either way.
On a bad day, this stock has moved -$352.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,717.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- label change · signal_labelmoderate change
Signal changed from 'mild_favorable' to 'mixed'.
As of June 16, 2026, the signal label changed to mixed, indicating a shift in sentiment. The risk dimension fell, suggesting a decrease in perceived risk. The earnings quality remains loss-making, and the management dimension is stable. The sector backdrop is a headwind, which may impact performance.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- DownsideHigh confidenceMonthsactive 4d
Watch for Q2 2026 total revenue results
Why it matters: Total revenue results will indicate if the company is on track to meet its $1.08-$1.18 billion guidance.
What confirms / what disproves
Confirms:Q2 2026 total revenue exceeds $300 million.
Disproves:Q2 2026 total revenue falls below $250 million.
Sector context
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PTCT yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting PTCT and other Healthcare names. Worth watching these names for early signals.
- If PTCT beats again next quarter like it did this past one (a big beat of +93% on the 2026-03-31 print), the momentum tends to extend, with Street estimates ratcheting up and the stock typically following.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for PTCT and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If PTCT reverses and cuts guidance after recently raising (RAISED as of 2026-05-07), that's the worst kind of move: a credibility hit on top of the lower number. Stocks usually get punished disproportionately for this.
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping PTCT and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-161d agoItem 8.01
Other Events. On June 15, 2026, PTC Therapeutics, Inc. (the “Company”) issued a press release announcing the pricing of its previously announced offering (the “Offering”) of $500.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2031 (the “Notes”). The Company also granted the initial purchasers an option to purchase, within the 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $50.0 million aggregate principa…
Capital allocationpositive
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
-1.3 vs last weeklatest as of 2026-06-17
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.